Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Zelboraf
Vemurafenib is an orally available small molecule kinase inhibitor indicated for the treatment of late-stage melanoma (skin cancer) that has spread to other parts of the body or cannot be removed by surgery and harbors a BRAF V600E mutation. It belongs to a class of drugs known as BRAF inhibitors, specifically targeting the mutated BRAF protein which plays a crucial role in the uncontrolled growth and division of cancer cells.
For the treatment of BRAF V600E mutation-positive unresectable or metastatic melanoma.
Vemurafenib can cause new skin cancers, including cutaneous squamous cell carcinoma and keratoacanthoma. Patients should be monitored regularly for skin lesions.
Outcome:
Decreased vemurafenib levels, reduced efficacy
Mechanism:
Increased metabolism
Outcome:
Decreased vemurafenib levels
Mechanism:
CYP3A4 induction
Outcome:
Slightly increased caffeine levels
Mechanism:
CYP1A2 inhibition
Most likely new formulation: Extended-release formulation (Year 2025, 80% confidence)
Based on current usage trends and emerging research, there is a 70% likelihood of vemurafenib being approved for additional indications within the next 5 years.
Kinase Inhibitor, Antineoplastic Agent
Aryl urea